PMID- 32493088
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20231111
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - A Randomized, Placebo-Controlled Trial Evaluating Changes in Peripheral 
      Neuropathy and Quality of Life by Using Low-Frequency Electrostimulation on 
      Breast Cancer Patients Treated With Chemotherapy.
PG  - 1534735420925519
LID - 10.1177/1534735420925519 [doi]
LID - 1534735420925519
AB  - Background: This study examined the effect of a portable low-frequency 
      electrostimulation (ES) device on patients diagnosed with chemotherapy-induced 
      peripheral neuropathy (CIPN) immediately after chemotherapy for breast cancer. 
      Methods: A single-center, randomized, placebo-controlled trial was conducted. A 
      total of 72 patients newly diagnosed with CIPN were enrolled and randomly placed 
      into the ES (n = 36) or the sham ES group (SES; n = 36). Duloxetine or pregabalin 
      was prescribed to all participants from the initial assessment. The devices for 
      14 days, at least twice a day, for at least 120 minutes. The primary outcomes 
      were the overall intensities of the CIPN symptoms as assessed using Numerical 
      Rating Scale (NRS). Secondary outcomes included Total Neuropathy Score (TNS), 
      European Organization for Research and Treatment of Cancer Quality of Life 
      (EORTC-QLQ), Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20), Functional 
      Assessment of Cancer Therapy-Breast (FACT-B), and Instrument on Pattern 
      Identification and Evaluation for CIPN (IPIE-CIPN). Results: No differences in 
      NRS scores were found between the patients in the ES and the SES group (P = 
      0.267). Patients in both groups showed significantly reduced CIPN intensities (ES 
      P < .001; SES P < .001). No significant differences between the groups were found 
      in TNS, EORTC-QLQ, CIPN20, and FACT-B. The general symptoms of CIPN diagnosed as 
      cold arthralgia showed significance only in the ES group (P = .006). Conclusion: 
      Compared with a placebo, the effectiveness of the low-frequency ES device with 
      pharmacological intervention was not significantly different, but a therapeutic 
      effect was possible.
FAU - Song, Si-Yeon
AU  - Song SY
AD  - Dunsan Korean Medicine Hospital of Daejeon University, Daejeon, Republic of 
      Korea.
FAU - Park, Ji-Hye
AU  - Park JH
AD  - Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea.
FAU - Lee, Jin Sun
AU  - Lee JS
AD  - Chungnam National University, Daejeon, Republic of Korea.
FAU - Kim, Je Ryong
AU  - Kim JR
AD  - Chungnam National University, Daejeon, Republic of Korea.
FAU - Sohn, Eun Hee
AU  - Sohn EH
AD  - Chungnam National University Hospital, Daejeon, Republic of Korea.
FAU - Jung, Mi Sook
AU  - Jung MS
AD  - Chungnam National University, Daejeon, Republic of Korea.
FAU - Yoo, Hwa-Seung
AU  - Yoo HS
AUID- ORCID: 0000-0003-3738-3239
AD  - Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea.
LA  - eng
SI  - CRiS/KCT0002357
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - *Breast Neoplasms/drug therapy
MH  - *Electric Stimulation Therapy
MH  - Female
MH  - Humans
MH  - *Peripheral Nervous System Diseases/chemically induced/therapy
MH  - Quality of Life
PMC - PMC7273579
OTO - NOTNLM
OT  - breast cancer
OT  - chemotherapy-induced peripheral neuropathy
OT  - health-related quality of life
OT  - low-frequency electrostimulation device
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/06/05 06:00
MHDA- 2021/08/19 06:00
PMCR- 2020/06/04
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/04 00:00 [pmc-release]
AID - 10.1177_1534735420925519 [pii]
AID - 10.1177/1534735420925519 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2020 Jan-Dec;19:1534735420925519. doi: 
      10.1177/1534735420925519.